ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Cytomeglovirus"

  • 2018 American Transplant Congress

    Altered Function of Cytomegalovirus Specific T Cells in Transplant Recipients

    L. Higdon,1 J. Trofe-Clark,2 S. Liu,1 N. Saligrama,1 K. Margulies,2 M. Davis,1 J. Maltzman.1,3

    1Stanford U, Stanford, CA; 2U Pennsylvania, Philadelphia, PA; 3VA Palo Alto, Palo Alto, CA.

    Background: Cytomegalovirus (CMV) reactivation is associated with increased morbidity and mortality in transplant recipients. CMV establishes latency for the host's lifetime and frequently reactivates. Immunosuppression,…
  • 2018 American Transplant Congress

    Clinical Significance of Tacrolimus Trough Level at the Early Period after Kidney Transplantation

    W. Park,1,2 S. Yeo,1 S. Kang,1,2 H. Park,1 K. Jin,1,2 S. Park,1,2 S. Han.1,2

    1Internal Medicine, Keimyung University School of Medicine, Daegu, Republic of Korea; 2Keimyung University Kidney Institute, Daegu, Republic of Korea.

    Background:The stable immunosuppressant level at the early period after kidney transplantation (KT) is one of the most important factors to decide the prognosis of KT.…
  • 2018 American Transplant Congress

    The TRANSFORM Study: Infection Outcomes with Everolimus Plus Reduced Calcineurin Inhibitor and Mycophenolate Plus Standard Calcineurin Inhibitor Regimens in De Novo Kidney Transplant Recipients

    F. Vincenti, J. Cruzado, S. Mulgaonkar, V. Garcia, D. Kuypers, M. Buchler, F. Citterio, U. Huynh-Do, W-.L. Luo, P. Bernhardt, C. Sommerer.

    TRANSFORM Study Group, Novartis Pharma AG, Basel, Switzerland.

    Purpose: Post-transplant (Tx) bacterial and viral infections are known to affect graft and patient survival. Accumulating evidence supports the protective effect of everolimus (EVR) against…
  • 2018 American Transplant Congress

    Primary Cytomegalovirus Infection in Seronegative Kidney Transplant Patients is Associated with Prolonged Cold Ischemic Time of Seropositive Donor Organs

    C. Falk,1,7 F. Schlott,2,7 K. Katsrintaki,1,7 D. Steubl,3 W. Puppe,4 C. Blume,5 H. Haller,6 L. Renders,3 U. Heemann,3 D. Busch,2 M. Neuenhahn.2,7

    1Institute of Transplant Immunology, IFB-Tx, Hannover Medical School, Hannover, Germany; 2Institute for Medical Microbiology, Immunology and Hygiene, Technical University Munich, Munich, Germany; 3Department of Nephrology, Technical University Munich, Munich, Germany; 4Institute of Virology, Hannover Medical School, Hannover, Germany; 5Institute of Technical Chemistry, Leibniz University Hannover, Hannover, Germany; 6Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany; 7DZIF TTU-IICH, DZIF, Hannover / Munich, Germany.

    Introduction: Human Cytomegalovirus (CMV) infection is still a major risk factor for immunocompromised patients, e.g. kidney recipients. Based on the CMV serostatus of donor (D)…
  • 2018 American Transplant Congress

    Clinical Utility of CMV-Specific CD8+ T-Cell Immune Competence Score in Lung and Heart-Lung Transplant Recipients at Risk of Cytomegalovirus Infection

    A. Meesing,1 R. Abraham,2 R. Razonable.1

    1Division of Infectious Diseases, Mayo Clinic, Rochester, MN; 2Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.

    Introduction: Cytomegalovirus (CMV) is a common infection that causes significant morbidity among lung and heart-lung (LHL) transplant recipients. We determined the clinical utility of global…
  • 2018 American Transplant Congress

    Cytomegalovirus (CMV) Infection in Small Intestinal and Multivisceral Transplant Recipients: The Role of Donor Selection on CMV Incidence and Outcomes

    H. Grewal, M. Czech, C. Matsumoto, M. Natarajan, J. Fraker, W. Fan, J. Timpone.

    Medstar Georgetown University Hospital, Washington DC.

    Introduction: CMV infection remains an important cause of morbidity, allograft enteritis, and allograft loss in small intestinal (SIT) and multivisceral transplant (MVT) recipients. As the…
  • 2018 American Transplant Congress

    Standard- versus Low-Dose Valganciclovir for Cytomegalovirus Prophylaxis in Intermediate-Risk Kidney Transplant Recipients

    N. Wilson, N. Sulejmani, A. Jantz, A. Patel, B. Summers.

    Henry Ford Hospital, Detroit, MI.

    Background: Although guidelines recommend valganciclovir (VGC) 900 mg daily for cytomegalovirus (CMV) prophylaxis in solid organ transplant patients, multiple centers have reported clinical success, reduced…
  • 2018 American Transplant Congress

    Identifying Specificity Groups in the CMV IE-1 T Cell Receptor Repertoire

    M. Lucia,1 F. Rubelt,2 S. Luque,3 S. Krams,1 C. Esquivel,1 O. Bestard,3 O. Martinez.1

    1Department of Surgery, Stanford University, Palo Alto; 2Institute for Immunity, Transplantation and Infection, Stanford University, Palo Alto; 3Experimental Nephrology, IDIBELL, Barcelona, Catalonia, Spain.

    Cytomegalovirus (CMV) continues to be a major problem for organ transplant recipients. T cells specific to the CMV antigens immediate-early (IE-1) and pp65 CMV govern…
  • 2017 American Transplant Congress

    Low Dose Valganciclovir for CMV Prophylaxis in the First Year of Kidney Transplantation.

    P. Klem,1 L. Al-Omar,2 J. Cooper,2 S. Davis,2 J. Gralla,2 D. Choe,1 A. Wiseman.2

    1Pharmacy, University of Colorado, Aurora, CO; 2Nephrology, University of Colorado, Aurora

    Valganciclovir (VGC) is the standard antiviral agent used for the prevention of CMV diseases in moderate and high risk renal transplant recipients, yet the optimal…
  • 2017 American Transplant Congress

    Improving Donor Screening for Cytomegalovirus (CMV): Is CMV IgG Avidity Better Than CMV IgM?

    H. Prince,1 M. Nowicki.1,2

    1Donor Screening Laboratory, VRL Eurofins, Los Angeles, CA; 2Mendez National Institute of Transplantation Foundation, Los Angeles, CA

    Study purpose: It is standard practice to test organ donors for CMV IgM as a marker of recent CMV infection (defined as primary infection within…
  • « Previous Page
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • 23
  • …
  • 33
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences